Meibomian Gland Dysfunction Market Report 2026

The meibomian gland dysfunction market size has grown strongly in recent years. It will grow from $4.42 billion in 2025 to $4.73 billion in 2026 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to increasing incidence of dry eye disease, higher screen time exposure, aging population growth, wider clinical recognition of mgd, availability of basic treatment options.

The meibomian gland dysfunction market size is expected to see strong growth in the next few years. It will grow to $6.12 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to increasing adoption of device-assisted therapies, rising investments in ophthalmic care, growing awareness of chronic eye conditions, expansion of home-use treatment devices, increasing focus on personalized eye care. Major trends in the forecast period include increasing adoption of advanced diagnostic tools, rising use of device-based therapies, growing preference for combination treatment approaches, expansion of home-based management solutions, enhanced focus on early disease detection.

The rising prevalence of eye diseases is expected to drive the growth of the meibomian gland dysfunction (MGD) market in the coming years. Eye diseases encompass any condition or disorder affecting the eye or visual system, impairing its structure, function, or overall health. The increase in eye disease cases is largely due to prolonged screen time and digital eye strain, which can lead to dryness, blurred vision, and long-term retinal damage from extended exposure to blue light. Meibomian gland dysfunction contributes to eye disease by destabilizing the tear film, causing inflammation, dryness, and an elevated risk of ocular surface disorders. For instance, in February 2025, according to the National Institutes of Health (NIH), a US-based government agency, the global prevalence of myopia is projected to rise to 36.59% by 2040 and 39.80% by 2050, with total cases expected to exceed 740 million by 2050. Therefore, the rising incidence of eye diseases is propelling the growth of the meibomian gland dysfunction (MGD) market.

Leading companies in the meibomian gland dysfunction market are focusing on innovative treatments such as prescription eye drop solutions to reduce tear evaporation and alleviate dry eye symptoms. Prescription eye drops, including anti-inflammatory or antibiotic formulations, help manage MGD by reducing inflammation, unclogging blocked glands, and stabilizing the tear film. For instance, in May 2023, Bausch + Lomb Corporation, a Canada-based eye health company, launched MIEBO (perfluorohexyloctane ophthalmic solution), a novel prescription eye drop for treating dry eye disease (DED). As the first and only prescription drop to directly target tear evaporation - the primary cause of DED - MIEBO forms a protective, long-lasting layer on the eye’s surface. Its water-free formulation provides effective and sustained relief, particularly for patients with dry eye symptoms linked to meibomian gland dysfunction.

In July 2023, CS Pharmaceuticals Limited, a UK-based pharmaceutical company, acquired AxeroVision Inc. for an undisclosed amount. Through this acquisition, CS Pharmaceuticals aims to expand its ophthalmology portfolio and accelerate the development of novel treatments for MGD-related dry eye disease, addressing a significant unmet medical need. AxeroVision Inc. is a US-based biotech company specializing in innovative therapies for meibomian gland dysfunction.

Major companies operating in the meibomian gland dysfunction market are Johnson And Johnson, Alcon Inc., Bausch Lomb Corporation, Santen Pharmaceutical, Lumenis Ltd, Topcon Healthcare Solutions Inc, AFT Pharmaceuticals, Sight Sciences Inc, OASIS Medical Inc, OCuSOFT Inc, Novaliq GmbH, Scope Ophthalmics Ltd, Medmont International Pty Ltd, Azura Ophthalmics Ltd, BlephEx LLC, Bruder Healthcare Company, ESW Vision Inc, MiBo Medical Group Inc, Kala Pharmaceuticals Inc, Allergan Eye Care, TearScience Inc, Sun Pharmaceutical Industries Ltd.

North America was the largest region in the meibomian gland dysfunction market in 2025. The regions covered in the meibomian gland dysfunction market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the meibomian gland dysfunction market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are affecting the meibomian gland dysfunction market by increasing costs of imported ophthalmic devices, diagnostic equipment, consumables, and pharmaceutical ingredients used in clinical and home-based treatments. Hospitals and ophthalmology clinics in North America and Europe are most impacted due to reliance on imported medical devices, while Asia-Pacific faces higher costs for advanced treatment systems. These tariffs are raising treatment costs and slowing technology adoption. At the same time, they are encouraging regional device manufacturing, localized supply chains, and innovation in cost-efficient ophthalmic solutions.

The meibomian gland dysfunction market research report is one of a series of new reports that provides meibomian gland dysfunction market statistics, including meibomian gland dysfunction industry global market size, regional shares, competitors with a meibomian gland dysfunction market share, detailed meibomian gland dysfunction market segments, market trends and opportunities, and any further data you may need to thrive in the meibomian gland dysfunction industry. This meibomian gland dysfunction market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Meibomian gland dysfunction (MGD) is a common eye condition in which the meibomian glands, located in the eyelids, become blocked or produce oil of abnormal quality. This disrupts the tear film, leading to symptoms such as dryness, irritation, inflammation, and blurry vision. MGD is a leading cause of dry eye disease and can vary in severity from mild to severe.

The primary treatment types of meibomian gland dysfunction include medication, surgery, and lifestyle modifications. Medication involves the use of drugs or other therapeutic agents to treat, manage, or prevent symptoms and conditions under medical supervision. MGD can be classified as obstructive, evaporative, or mixed types, with severity ranging from mild to moderate to severe. Treatments are distributed through channels such as hospitals, clinics, pharmacies, and online retailers and are used by end users including hospitals, ophthalmology clinics, and home care settings.

The meibomian gland dysfunction market consists of revenues earned by entities by providing services such as diagnostic services, customized dry eye management plans, and thermal pulsation treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The meibomian gland dysfunction market also includes sales of artificial tears and lubricating eye drops, omega-3 supplements, prescription medications, and intense pulsed light (IPL) therapy devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.